Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Pfizer’s abrocitinib hits endpoints in late-stage atopic dermatitis study

pharmatimesMarch 23, 2020

Tag: Pfizer , abrocitinib , atopic dermatitis

PharmaSources Customer Service